User profiles for Anton I. Rosenbaum

Anton Rosenbaum

AstraZeneca
Verified email at astrazeneca.com
Cited by 1455

Niemann‐Pick type C disease: molecular mechanisms and potential therapeutic approaches

AI Rosenbaum, FR Maxfield - Journal of neurochemistry, 2011 - Wiley Online Library
… CDs can be delivered via pinocytosis to LE/LY, where they can replace the function of
NPC1 and NPC2 proteins (Rosenbaum et al. 2010b) and promote cholesterol esterification by …

Endocytosis of beta-cyclodextrins is responsible for cholesterol reduction in Niemann-Pick type C mutant cells

AI Rosenbaum, G Zhang, JD Warren… - Proceedings of the …, 2010 - National Acad Sciences
Niemann-Pick type C disease (NPC) is a lysosomal storage disorder causing accumulation
of unesterified cholesterol in lysosomal storage organelles. Recent studies have shown that …

The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in nonhuman primates and has an extended half-life in humans

…, J Dunyak, Y Huang, AI Rosenbaum… - Science translational …, 2022 - science.org
Despite the success of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
vaccines, there remains a need for more prevention and treatment options for individuals …

Thiadiazole carbamates: potent inhibitors of lysosomal acid lipase and potential Niemann− Pick type C disease therapeutics

AI Rosenbaum, CC Cosner, CJ Mariani… - Journal of medicinal …, 2010 - ACS Publications
Niemann−Pick type C (NPC) disease is a lysosomal storage disorder characterized at the
cellular level by abnormal accumulation of cholesterol and other lipids in lysosomal storage …

[HTML][HTML] Bioanalytical methods and strategic perspectives addressing the rising complexity of novel bioconjugates and delivery routes for biotherapeutics

…, JK Meissen, S Mou, M Liang, AI Rosenbaum - BioDrugs, 2022 - Springer
In recent years, an increase in the discovery and development of biotherapeutics employing
new modalities, such as bioconjugates or novel routes of delivery, has created bioanalytical …

[HTML][HTML] ADME considerations and bioanalytical strategies for pharmacokinetic assessments of antibody-drug conjugates

S Mou, Y Huang, AI Rosenbaum - Antibodies, 2018 - mdpi.com
Antibody-drug conjugates (ADCs) are a unique class of biotherapeutics of inherent
heterogeneity and correspondingly complex absorption, distribution, metabolism, and excretion (…

[HTML][HTML] Development of an orally delivered GLP-1 receptor agonist through peptide engineering and drug delivery to treat chronic disease

…, C Patel, L Liang, L Tseng, Y Huang, AI Rosenbaum… - Scientific reports, 2021 - nature.com
Peptide therapeutics are increasingly used in the treatment of disease, but their administration
by injection reduces patient compliance and convenience, especially for chronic diseases…

First-in-human, phase 1 dose-escalation study of biparatopic anti-HER2 antibody–drug conjugate MEDI4276 in patients with HER2-positive advanced breast or …

…, AR Tan, AM Storniolo, K Balic, AI Rosenbaum… - Molecular Cancer …, 2021 - AACR
MEDI4276 is a biparatopic tetravalent antibody targeting two nonoverlapping epitopes in
subdomains 2 and 4 of the HER2 ecto-domain, with site-specific conjugation to a tubulysin-…

Design and preclinical evaluation of a novel B7-H4–directed antibody–drug conjugate, AZD8205, alone and in combination with the PARP1-selective inhibitor …

…, M Davies, A Lewis, Y Huang, AI Rosenbaum… - Clinical Cancer …, 2023 - AACR
Purpose: We evaluated the activity of AZD8205, a B7-H4–directed antibody–drug conjugate
(ADC) bearing a novel topoisomerase I inhibitor (TOP1i) payload, alone and in combination …

AZD7442 demonstrates prophylactic and therapeutic efficacy in non-human primates and extended half-life in humans

…, LI Cheng, J Dunyak, Y Huang, AI Rosenbaum… - Medrxiv, 2021 - medrxiv.org
Despite the success of SARS-CoV-2 vaccines, there remains a need for more prevention
and treatment options for individuals remaining at risk of COVID-19. Monoclonal antibodies (…